Semaglutide, a glucagon-like peptide‑1 receptor agonist (GLP‑1 RA) marketed globally as Ozempic, Wegovy, and Rybelsus, has transformed the pharmacological management of type 2 diabetes and obesity, often achieving weight loss previously seen only with bariatric surgery. India, which now ranks among the highest in the world for both diabetes and obesity, has begun to integrate […]